|Bid||0.00 x 2200|
|Ask||0.00 x 800|
|Day's Range||91.33 - 94.89|
|52 Week Range||76.41 - 100.15|
|Beta (3Y Monthly)||0.63|
|PE Ratio (TTM)||39.74|
|Forward Dividend & Yield||2.00 (2.12%)|
|1y Target Est||N/A|
Medtronic (MDT) demonstrated improved performances at CER on growth in all business segments. However, costs continue to escalate.
Medical device maker Medtronic Plc on Tuesday beat analysts' profit estimates for the second quarter and boosted its annual revenue growth outlook, driven by robust sales at its cardiac and surgical product units, sending its shares up 3 percent. Sales at the unit rose 26 percent helped by the strong adoption of MiniMed 670G system in the United States. Medtronic's MiniMed 670G "artificial pancreas" is the first device to automatically deliver the right dose of insulin to patients with type 1 diabetes.
Investing.com - Medtronic (NYSE:MDT) reported second quarter earnings that beat analysts' expectations on Tuesday and revenue that topped forecasts.
Medtronic's (MDT) resolve to take over the Israel-based robotic surgical guidance systems company, Mazor Robotics, adheres to its goal to grow in the sphere of robotics spine surgery.
Medtronic (MDT) delivered earnings and revenue surprises of 7.02% and 1.77%, respectively, for the quarter ended October 2018. Do the numbers hold clues to what lies ahead for the stock?
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 19) Merck & Co., Inc. (NYSE: MRK ) Down In The Dumps (Biotech ...
Check out the companies making headlines before the bell: Target TGT – The retailer earned an adjusted $1.09 per share for the third quarter , 3 cents a share below estimates. Revenue exceeded forecasts, however, and comparable-store sales were up 5.
Medtronic PLC reported second-quarter profit and revenue beats early Tuesday, but also said it has taken hits from foreign exchange rates and projected China tariffs. Company shares slumped 0.2% in premarket trade. Earnings for the latest quarter declined to $1.115 billion, or 82 cents per share, from $2.017 billion, or $1.48 per share in the year-earlier period. Adjusted earnings-per-share were $1.22, above the FactSet consensus of $1.15. Revenue rose to $7.481 billion from $7.050 billion, above the FactSet consensus of $7.348 billion. The company said that if exchange rates hold for the rest of the fiscal year, fiscal 2019 revenue would be negatively affected by roughly $420 million to $520 million. Medtronic also said that "operational outperformance" in the first half of fiscal year 2019 had allowed the company to absorb expenses like foreign exchange impacts and the projected impacts of China tariffs. It continues to expect fiscal year 2019 adjusted EPS of $5.10 to $5.15, compared with the FactSet consensus of $5.12. Medtronic shares have lifted 0.4% over the last three months, compared with a 5.8% decline in the S&P 500 and a 2.9% decline in the Dow Jones Industrial Average .
Omar Ishrak became the CEO of Medtronic plc (NYSE:MDT) in 2011. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at other big companies. After Read More...
On a per-share basis, the Dublin-based company said it had net income of 82 cents. Earnings, adjusted for amortization costs and restructuring costs, came to $1.22 per share. The results surpassed Wall ...
Medical device maker Medtronic Plc reported a 6 percent rise in quarterly revenue on Tuesday, helped by higher sales in its cardiac and vascular business. Net income attributable to the company fell to ...
Medtronic, Inc. (NYSE: MDT ) announces its next round of earnings this Tuesday, Nov. 20. Here is Benzinga's everything-that-matters guide for the Q2 earnings announcement. Earnings and Revenue Based on ...
Medtronic (MDT) gains traction from the U.S. launch of its Guardian Connect product. This enables the company to further capture a considerable share in the $1-billion standalone CGM market.
The "Mad Money" host will be watching for include key housing data, as well as news on interest rates and a potential trade deal. CNBC's Jim Cramer will be seeking out "man-made" buying opportunities for investors in the short week before Thanksgiving Day. "Immediately, there were questions about ... the validity or the sincerity of both of these statements," Cramer noted, referencing his own concern about the Fed's lack of rigor in its policymaking.
Medtronic (MDT) is expected to maintain a decent market share in the core pacing banking, backed by the continued rollout of Micra Transcatheter Pacing System.
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.